Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants

被引:33
|
作者
Zhao, XD
Chen, FP
Megaw, AG
Sullender, WM
机构
[1] Univ Alabama, Dept Pediat, Birmingham, AL 35233 USA
[2] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA
来源
JOURNAL OF INFECTIOUS DISEASES | 2004年 / 190卷 / 11期
关键词
D O I
10.1086/425515
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Palivizumab (PZ) is the only monoclonal antibody in use against a human infectious disease. PZ is given as prophylaxis against infection with respiratory syncytial virus (RSV). An RSV escape mutant, MP4, has been shown to resist PZ prophylaxis in cotton rats. Methods. To further define the potential of RSV to resist prophylaxis, additional PZ-resistant viruses were selected in cell culture and were tested for susceptibility to PZ in cotton rats. Results. Mutant MS412 had an A-->C mutation at nucleotide position 827 in the F gene, resulting in an amino acid change from Lys to Gln at position 272. Mutant F212 had an A-->T mutation at position 816, leading to an amino acid change from Asn to Ile at position 268. In vitro, F212 had impaired growth kinetics. In cell culture, F212 was partially and MS412 was completely resistant to PZ neutralization. A single prophylactic dose of 15 mg/kg PZ protected cotton rats from infection with F212 but not with MS412. Conclusion. Both in vitro and in vivo, individual RSV PZ escape mutants varied in their susceptibility to PZ. Mutations associated with resistance to PZ did not always result in failure of PZ prophylaxis.
引用
收藏
页码:1941 / 1946
页数:6
相关论文
共 50 条
  • [31] Palivizumab prophylaxis, respiratory syncytial virus and subsequent development of asthma
    Igde, M.
    Kabasakal, H.
    Ozturk, O.
    Karatekin, G.
    Aygun, C.
    [J]. ALLERGY, 2016, 71 : 534 - 534
  • [32] Immunoprophylaxis of group B respiratory syncytial virus infection in cotton rats
    Faverio, LA
    Piazza, FM
    Johnson, SA
    Darnell, MER
    Ottolini, MG
    Hemming, VG
    Prince, GA
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (04): : 932 - 934
  • [33] Revised indications for the use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the prevention of respiratory syncytial virus infections
    Abramson, JS
    Baker, CJ
    Baltimore, RS
    Bocchini, JA
    Long, SS
    McMillan, JA
    Meissner, HC
    Powell, KR
    Prober, CG
    Rennels, MB
    Saari, TN
    Weiner, LB
    Blackmon, L
    Batton, DG
    Bell, EF
    Denson, SE
    Engle, WA
    Kanto, WP
    Martin, GI
    Stark, AR
    [J]. PEDIATRICS, 2003, 112 (06) : 1447 - 1452
  • [34] Detection of ON1 and novel genotypes of human respiratory syncytial virus and emergence of palivizumab resistance in Lebanon
    Abou-El-Hassan, Hadi
    Massaad, Elie
    Soudani, Nadia
    Assaf-Casals, Aia
    Shaker, Rouba
    Khoury, Mireille Lteif
    Ghanem, Soha
    Karam, Maria
    Andary, Rabih
    Saito, Reiko
    Dbaibo, Ghassan
    Zaraket, Hassan
    [J]. PLOS ONE, 2019, 14 (02):
  • [35] Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
    Lina Bollani
    Eugenio Baraldi
    Gaetano Chirico
    Andrea Dotta
    Marcello Lanari
    Antonello Del Vecchio
    Paolo Manzoni
    Antonio Boldrini
    Piermichele Paolillo
    Sandra Di Fabio
    Luigi Orfeo
    Mauro Stronati
    Costantino Romagnoli
    [J]. Italian Journal of Pediatrics, 41
  • [36] Effectiveness of Palivizumab in Respiratory Syncytial Virus Prophylaxis in Children with Cystic Fibrosis
    Winterstein, Almut G.
    Eworuke, Efe
    Xu, Dandan
    Schuler, Pamela
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2012, 21 : 148 - 148
  • [37] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Candice Bjornson
    Parco Chan
    Abby Li
    Bosco Paes
    Krista L. Lanctôt
    Ian Mitchell
    [J]. European Journal of Clinical Microbiology & Infectious Diseases, 2018, 37 : 1113 - 1118
  • [38] Palivizumab prophylaxis for respiratory syncytial virus in infants with cystic fibrosis: is there a need?
    Bjornson, Candice
    Chan, Parco
    Li, Abby
    Paes, Bosco
    Lanctot, Krista L.
    Mitchell, Ian
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2018, 37 (06) : 1113 - 1118
  • [39] Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
    Bollani, Lina
    Baraldi, Eugenio
    Chirico, Gaetano
    Dotta, Andrea
    Lanari, Marcello
    Del Vecchio, Antonello
    Manzoni, Paolo
    Boldrini, Antonio
    Paolillo, Piermichele
    Di Fabio, Sandra
    Orfeo, Luigi
    Stronati, Mauro
    Romagnoli, Costantino
    [J]. ITALIAN JOURNAL OF PEDIATRICS, 2015, 41
  • [40] Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era
    Taylor, Richard S.
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (15) : E523 - E523